Aptose Biosciences Inc. (0UI8.L)

2,6000 -4,2700 (-62,15%) Alla chiusura: 03:52PM BST

Aptose Biosciences Inc.

251 Consumers Road
Suite 1105
Toronto, ON M2J 4R3
Canada
647 479 9828
https://www.aptose.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 35

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. William G. Rice Ph.D.	Chairman, President, CEO & Chief Accounting Officer	892,06k	N/D	1959
Mr. Fletcher Payne	Senior VP, CFO, Chief Business Officer & Secretary	644,38k	N/D	1963
Dr. Rafael Bejar M.D., Ph.D.	Senior VP & Chief Medical Officer	684,06k	N/D	1973
Dr. Marc Wiles Ph.D.	Senior Vice President of Regulatory Affairs	N/D	N/D	N/D
Mr. Brooks Ensign M.B.A.	VP & Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CAD.

Descrizione

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Governance aziendale

L'ISS Governance QualityScore di Aptose Biosciences Inc. al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.